Thank you, Bill, and thank you for joining us on Calyxt's financial results and corporate update call today. Today, I would like to walk you through our progress over the past few months before turning the call over to Bill for a financial update. Despite unprecedented headwinds in the capital markets and the macro economy and the resulting liquidity challenges for the company, we have made substantial progress across numerous fronts within the areas of business development, licensing, infrastructure partnership and the advancement of chemistries under development, specifically the successful engineering of a key ingredient used in personal care products and vaccines as well as accepting membership in an important Department of Defense-sponsored manufacturing initiative that opens the door for Calyxt to federal grants. We announced on October 25 that we had made substantial technical progress by successfully using a Calyxt-engineered Plant Cell Matrix to produce squalene. Squalene is an important ingredient in many personal care products and vaccine adjuvants, including several strands of flu and COVID-19 vaccines. Traditionally sourced from shark liver, many companies who require the ingredient for their products have already begun to seek out alternative squalene sources that represent a more sustainable solution. With increasing demand for natural ingredients in cosmetics, along with the urgency to develop more vaccines that are effective at boosting immune response, the global squalene market represents a significant and growing market opportunity. Furthermore, the production of squalene validates the promise of our platform to engineer plant metabolism to produce innovative high-value plant-based chemistries for use in our customers' materials and products across the end markets of cosmeceuticals, nutraceuticals and pharmaceuticals. In the third quarter of 2022, we received 37 new chemistries from potential customers for evaluation, bringing the total number of chemistries cumulatively evaluated for development with our PlantSpring platform and for production in our BioFactory to 132. Of the 132 chemistries, 43 have met our target product profile criteria and are subject to further evaluation and discussion with potential customers. Additionally, the evaluated chemistries include several that were identified by potential customers as having been unsuccessfully attempted by others in the synthetic biology industry. Our current customer projects under development remain on track. We continue to progress the pilot project for a major consumer packaged goods company with delivery of the plant-based chemistry expected by early 2023. This delivery has the potential to lead to a development agreement for this and potentially other chemistries. Similarly, the development of our soybean-based palm oil alternative plant trait continues to progress, and we expect to achieve the first $100,000 milestone payment as early as the fourth quarter of 2022. The overall project is scheduled to be completed in the first quarter of 2024, at which time the second milestone payment of $100,000 would be due. We also announced and signed an agreement with our first infrastructure partner, Evologic Technologies, to further develop and scale our PCM technology platform. The agreement supports the continued build-out of our plant-based synthetic biology capabilities and will power our speed-to-scale strategy and supports our ability to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets. Evologic's contract development and manufacturing services based on its proprietary bioprocesses platform and technology supports companies like ours who are delivering unique and sustainable bioproducts. We anticipate sending the first PCM that will produce an engineered plant-based chemistry squalene to Evologic for scaling in the fourth quarter of 2022. I would also like to note that we accepted membership to BioMADE, a Department of Defense-sponsored, or DoD, manufacturing innovation initiative. As a result, Calyxt is now part of a network comprised of synthetic biology companies, including Ginkgo Bioworks and Amyris, top-tier academic institutions, research-focused, not-for-profits, and the United States government agencies dedicated to innovating and growing the bioeconomy. Membership also enables us to apply for federal government grants to advance research in plant-based biomanufacturing. We are very pleased to be a member of this organization and to potentially advance research for the DoD in the area of plant-based sustainable solutions. We had a truly productive quarter, and the team continues to make substantial progress despite challenging global macroeconomic dynamics and unprecedented headwinds in the capital markets. At the end of September, our Board of Directors announced that it is evaluating a full range of potential strategic alternatives and that it has to engage Canaccord Genuity as an adviser. This effort is ongoing, and it demonstrates Calyxt's commitment to optimizing value for shareholders. We unequivocally believe in the potential of our technology. The progress we have made across multiple fronts over the past several months demonstrates our momentum and provides important validation of the work we do. I'd like to now turn the call over to Bill, who will cover our third quarter financial results. Bill?